Precision Medicine Quarterly

Moderna and Thermo Fisher Scientific Announce Long-Term Strategic Collaboration

2022-02-25T12:15:46-05:00February 25th, 2022|

Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, today announced a 15-year strategic collaboration agreement to enable dedicated large-scale manufacturing in the U.S. of Spikevax®, Moderna’s COVID-19 vaccine, and other investigational mRNA medicines in its pipeline. [...]

Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo (nivolumab) plus Chemotherapy for First-Line Treatment

2022-02-25T12:11:39-05:00February 25th, 2022|

Bristol Myers Squibb (NYSE: BMY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval of Opdivo (nivolumab) in combination with fluoropyrimidine- and platinum-based chemotherapy for the first-line treatment of adult patients with unresectable advanced, recurrent, or metastatic esophageal squamous cell carcinoma (ESCC) [...]

Fulgent Genetics Announces Strategic Investment in Spatial Genomics

2022-02-25T12:05:13-05:00February 25th, 2022|

Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based genetic testing company focused on transforming patient care in oncology, infectious and rare diseases, and reproductive health, today announced a strategic investment in Spatial Genomics, Inc. (“Spatial”), a leading developer of sequential fluorescence in situ hybridization (seqFISH) technology. Fulgent Genetics is investing up [...]

Scipher Medicine Closes $110 Million Financing

2022-02-25T12:01:24-05:00February 25th, 2022|

Scipher Medicine, a precision immunology company matching each patient with their most effective therapy, today announced the completion of a $110 million financing. The round is led by Cowen Healthcare Investments, with participation from new investors Neuberger Berman, Hitachi Ventures, Laurion Capital, and Monashee Investment Management. Existing investors Northpond Ventures, aMoon, Khosla Ventures, Optum [...]

PrecisionLife announces appointment of Colin Stubberfield as SVP Drug Discovery to lead development of its precision medicine programs

2022-02-21T09:05:47-05:00February 21st, 2022|

PrecisionLife Limited, a global techbio company driving precision medicine in chronic diseases with drug discovery, clinical development, and healthcare solutions based on its unique insights into disease biology, announces the appointment of Colin Stubberfield, Ph.D. as SVP Drug Discovery. He will be based at the Company’s UK headquarters in Oxfordshire, UK. Dr Stubberfield brings [...]

Blueprint Medicines Reports Fourth Quarter and Full Year 2021 Results

2022-02-18T08:58:43-05:00February 18th, 2022|

Blueprint Medicines Corporation (NASDAQ: BPMC) today reported financial results and provided a business update for the fourth quarter and full year ended December 31, 2021. "Following a year of outstanding execution across our portfolio, we are well positioned in 2022 to drive significant year-over-year product revenue growth, achieve multiple anticipated clinical data milestones for [...]

Technology-Driven Precision Medicine Company Variantyx Secures $41.5M in Funding

2022-02-18T08:51:51-05:00February 18th, 2022|

Variantyx, a technology-driven precision medicine company providing advanced genomic testing for the rare genetic disorders, reproductive health, and precision oncology markets, today announced they have secured $41.5M in funding. The series C-2 funding round, led by New Era Capital Partners and includes Peregrine Ventures, Robert Bosch Venture Capital, 20/20 HealthCare Partners, and Pitango HealthTech, [...]

Synthego Raises $200 Million to Accelerate the Field of CRISPR-Based Medicines from Early-Phase Research to the Clinic

2022-02-18T08:49:18-05:00February 18th, 2022|

Synthego, the genome engineering company, today announced it has raised $200 million of growth capital, including a Series E financing led by Perceptive Advisors. Also participating in the round were new investors SoftBank Vision Fund 2, Declaration Partners, Laurion Capital Management, Logos Capital, GigaFund and Chimera Abu Dhabi and existing investors Wellington Management, RA [...]

Precision Medicine Leader Scott Megill Named One of The Top 25 Biotech CEOs of 2022

2022-02-17T11:19:39-05:00February 17th, 2022|

Leading the way in delivering cutting-edge personalized medication safety programs, Coriell Life Sciences’ President and CEO Scott Megill has been recognized as one of The Top 25 Biotech CEOs of 2022 by The Healthcare Technology Report. “Over the past year, these leading biotechnology executives and their organizations have demonstrated ingenuity, skill, and perseverance in [...]

Astra Zeneca Reports Full year and Q4 2021 results

2022-02-10T17:34:06-05:00February 10th, 2022|

Pascal Soriot, Chief Executive Officer, AstraZeneca, said: “AstraZeneca continued on its strong growth trajectory in 2021, with industry-leading R&D productivity, five of our medicines crossing new blockbuster thresholds, and the acquisition and integration of Alexion. We also delivered on our promise of broad and equitable access to our COVID-19 vaccine with 2.5 billion doses [...]

Go to Top